lupus
Exagen Posts Flat to Slight Decline in Preliminary Q4 Report, Gets Conditional NY Approval
The company received conditional approval from New York state for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays.
Exagen Q3 Revenues Decline 7 Percent
The firm said its Q3 revenues were negatively impacted by $1.2 million in one-time adjustments.
Exagen Licenses Lupus Nephritis Biomarkers From Johns Hopkins University
The company plans to develop the biomarkers into tests to help with diagnostic and treatment decisions by providing insight into a specific patient's lupus nephritis.
Werfen Nabs 510(k) for Connective Tissue Disease Reagent
The reagent is used to aid in the diagnosis of mixed connective tissue disease, systemic lupus erythematosus, and other connective tissue diseases.
AliveDx Nabs CE Marks for Connective Tissue Disease Tests
AliveDx, formerly Quotient, received the regulatory clearance for a pair of immunoassays designed for use on its fully automated MosaiQ microarray platform.